» Articles » PMID: 26937410

Two Consecutive Partial Liver Transplants in a Patient with Classic Maple Syrup Urine Disease

Overview
Specialty Endocrinology
Date 2016 Mar 4
PMID 26937410
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Maple syrup urine disease is caused by a deficiency in the branched chain ketoacid dehydrogenase (BCKAD) complex. This results in the accumulation of branched chain amino acids (BCAA) and branched chain ketoacids in the body. Even when aggressively treated with dietary restriction of BCAA, patients experience long term cognitive, neurological and psychosocial problems. Liver transplantation from deceased donors has been shown to be an effective modality in introducing adequate BCKAD activity, attaining a metabolic cure for patients. Here, we report the clinical course of the first known patient with classic MSUD who received two consecutive partial liver grafts from two different living non-carrier donors and his five year outcome posttransplant. We also show that despite the failure of the first liver graft, and initial acute cellular rejection of the second liver graft in our patient, his metabolic control remained good without metabolic decompensation.

Citing Articles

Genetic analysis by targeted next-generation sequencing and novel variation identification of maple syrup urine disease in Chinese Han population.

Fang X, Zhu X, Feng Y, Bai Y, Zhao X, Liu N Sci Rep. 2021; 11(1):18939.

PMID: 34556729 PMC: 8460745. DOI: 10.1038/s41598-021-98357-2.


Hyperleucinosis during infections in maple syrup urine disease post liver transplantation.

Guilder L, Prada C, Saenz S, Jain-Ghai S, Karp N, Mazariegos G Mol Genet Metab Rep. 2021; 27:100763.

PMID: 33996492 PMC: 8102797. DOI: 10.1016/j.ymgmr.2021.100763.

References
1.
Simon E, Schwarz M, Wendel U . Social outcome in adults with maple syrup urine disease (MSUD). J Inherit Metab Dis. 2007; 30(2):264. DOI: 10.1007/s10545-007-0475-4. View

2.
Shellmer D, DeVito Dabbs A, Dew M, Noll R, Feldman H, Strauss K . Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. Pediatr Transplant. 2010; 15(1):58-64. PMC: 3050647. DOI: 10.1111/j.1399-3046.2010.01411.x. View

3.
Mazariegos G, Morton D, Sindhi R, Soltys K, Nayyar N, Bond G . Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr. 2011; 160(1):116-21.e1. PMC: 3671923. DOI: 10.1016/j.jpeds.2011.06.033. View

4.
Strauss K, Wardley B, Robinson D, Hendrickson C, Rider N, Puffenberger E . Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010; 99(4):333-45. PMC: 3671925. DOI: 10.1016/j.ymgme.2009.12.007. View

5.
Suryawan A, Hawes J, Harris R, Shimomura Y, JENKINS A, Hutson S . A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr. 1998; 68(1):72-81. DOI: 10.1093/ajcn/68.1.72. View